weight loss
Tirzepatide
Tirzepatide
A dual GLP-1 and GIP receptor agonist. In head-to-head trials, tirzepatide outperformed semaglutide for weight loss.
How it works
Tirzepatide activates both GLP-1 and GIP receptors, producing stronger appetite suppression and metabolic effects than single-agonist drugs. The dual mechanism supports greater fat loss with comparable tolerability.
Benefits
- Up to 22.5% body weight reduction at 72 weeks (SURMOUNT-1)
- Dual incretin action, stronger than GLP-1 alone
- Improved lipid profile and blood pressure markers
- Weekly self-administered injection
Protocol
Weekly titration starting at 2.5mg, escalating monthly based on response and tolerability.
Frequently asked
Is tirzepatide safer than semaglutide?
Side effect profiles are similar. Your prescribing physician will help determine which molecule fits your medical history and goals.
Found in the Lean protocol
Sustainable weight loss, doctor-guided.
Prescription GLP-1, delivered
Information on this page is for educational purposes only and does not replace medical advice. Peptide therapy requires a valid prescription from a licensed physician.